Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

149 49,465

Net cash provided by operating

activities 282,777 274,321

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and

equipment (55,689) (70,887)

Acquisition of intangible assets (25,575) (99,152)

Investment in third party (6,242) -

Proceeds from sale of investment

in third party - 12,291

Sales and maturities of

available-for-sale investments 7,596 28,212

Purchases of available-for-sale

investments - (71,398)

Net cash used for investing

activities (79,910) (200,934)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercises of

common stock options 37,185 74,375

Windfall tax benefits from

stock-based compensation 4,592 9,934

Acquisition of treasury stock (24) (128)

Payments on and retirements of

long-term debt (216,093) (2,902)

Net cash (used for) provided

by financing activities (174,340) 81,279

EFFECT OF EXCHANGE RATE CHANGES ON

CASH AND CASH EQUIVALENTS (601) 10,804

NET INCREASE IN CASH AND CASH

EQUIVALENTS 27,926 165,470

CASH AND CASH EQUIVALENTS, BEGINNING

OF PERIOD 818,669 496,512

CASH AND CASH EQUIVALENTS, END OF

PERIOD
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... The next-generation sequencing (NGS) clinical market is poised for huge ... industry. BCC Research reveals in its new report that the market drivers of this ... growing need for better diagnostics as part of a molecular diagnostics trend. , The ...
(Date:7/1/2015)... HAMILTON, Bermuda , July 1, 2015 /PRNewswire/ ... biopharmaceutical company focused on the treatment of dementia, ... investor briefing on July 22 at 5:45 p.m. ... at the Alzheimer,s Association International Conference 2015 (AAIC). ... following remarks: , Dr. Lawrence ...
(Date:7/1/2015)... PHILADELPHIA , July 1, 2015 ... technology will ... s evidence-based clinical s olutions suite ... scientific, technical and medical information products and services, announced today ... -based clinical decision support (CDS) technology company. InferMed,s ...
(Date:7/1/2015)... 1, 2015  UCB, a multinational biopharmaceutical company, ... leader in designing, transforming, and running intelligent business ... recognition of their close collaboration in driving transformation ... business services (GBS) finance organization. The ... that work together effectively to embrace the innovative ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... July 7 VisEn Medical Inc., a leader in fluorescence ... commercial launch of its new Cat-K FAST ... activity associated with disease progression and therapeutic response in vivo ... biomarker and therapeutic target in a range of bone-related diseases, including ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... the generic version of AstraZeneca,s prostate cancer treatment Casodex(R), which ... 12 months ending March 31 for the same strength, according ...
... and SAN MATEO, Calif., July 7 King Pharmaceuticals, Inc. (NYSE: ... PTIE ) today announced that on July 2, 2009, King met ... Complete Response Letter regarding the New Drug Application (NDA) for REMOXY(R). ... path forward to resubmit the REMOXY(R) NDA and to address all ...
Cached Biology Technology:VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent 2King and Pain Therapeutics Announce REMOXY(R) NDA Update 2King and Pain Therapeutics Announce REMOXY(R) NDA Update 3
(Date:6/24/2015)... YORK , June 24, 2015 This ... market, over the next six years. It contains an ... the industry, along with their impact from the short, ... It also discusses the industry, market, and technology trends ... that the need of concerned authorities to efficiently manage ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
(Date:6/23/2015)... , June 23, 2015   Valencell, ... the results of a recent study that illustrates ... the wrist during activity. In a study conducted ... compared along with the Apple Watch against a ... heart rate during activity. The study demonstrated that ...
Breaking Biology News(10 mins):Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... a recent academic review, a University of Minnesota professor in ... opposed to specific nutrients, may be key to having a ... in food industry and government, where marketers and regulators tend ... specific vitamins and added supplements in food products, not the ...
... and EUMETSAT, the European Organisation for the Exploitation ... provide essential launch control services for the last ... MSG-4. Under the agreement, ESA will provide ... orbit phase (LEOP), which involves moving the satellite ...
... P&G Beauty announced that they successfully sequenced the complete ... naturally occurring fungus responsible for the onset of dandruff ... the genome sequencing are published in todays online edition ... Dandruff and seborrheic dermatitis affect more than 50 ...
Cached Biology News:Foods, not specific nutrients, may be key to good health 2ESA to provide essential launch control services to EUMETSAT 2ESA to provide essential launch control services to EUMETSAT 3Scientists complete genome sequence of fungus responsible for dandruff, skin disorders 2Scientists complete genome sequence of fungus responsible for dandruff, skin disorders 3
... emerging as a powerful new tool for ... only amino groups have been able to ... as our Sulfo-SBED. Sulfhydryl-reactive Mts-Atf-Biotin and its ... to the protein interaction tool chest that ...
... a compact benchtop and stackable multi-function ... with a large display screen to ... Air circulation inside to evenly distribute ... be easily calibrated from the microprocessor ...
... Nonanoyl-N-methylglucamide White solid. ... be readily removed by dialysis. Useful ... ≥98% by HPLC. Absorbance (10%, ... 2 O. CMC 19 - 25 ...
...
Biology Products: